The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Latest Psoriatic Arthritis Management Insights

The Latest Psoriatic Arthritis Management Insights

October 11, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and given rheumatologists information they can use to optimize care.

You Might Also Like
  • Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails
  • Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
Also By This Author
  • Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

In the original session, Philip Mease, MD, clinical professor at the University of Washington School of Medicine and director of rheumatology research at the Swedish Medical Center, Seattle, discussed many of the key trials in psoriatic arthritis and summarized recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the ACR and EULAR. Some of the core themes that emerged were the ideas that different pathophysiologic mechanisms may explain the different domains of psoriatic arthritis disease activity (i.e., arthritis, enthesitis, skin and nail involvement, etc.) and that the role of methotrexate in the treatment of psoriatic arthritis is still a point of some debate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Today, Dr. Mease still emphasizes the importance of head-to-head studies in evaluating treatments for psoriatic arthritis and, in this regard, three studies stand out and deserve close attention from clinicians.

Research Behind Therapies

The first study is the SEAM-PsA trial, which sought to evaluate the efficacy of methotrexate monotherapy, etanercept monotherapy or methotrexate and etanercept in combination in patients with early psoriatic arthritis.1 Dr. Mease, the lead author of this large-scale, randomized, controlled clinical trial, says the research centered on patients in the early disease stage; participants had a median disease duration of just 0.6 years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The primary end point of the study was ACR20, and Minimal Disease Activity was a key secondary end point. Patients treated with etanercept monotherapy achieved ACR20 and Minimal Disease Activity in similar numbers as those in the methotrexate/etanercept combination arm (61% and 65% for ACR20, and 36% and 36% for Minimal Disease Activity, respectively). This finding was of note because it supports the use of tumor necrosis factor-α inhibitor monotherapy in patients with psoriatic arthritis.

Dr. Mease

Another interesting finding in this study was that methotrexate monotherapy works surprisingly well for many patients, with 51% of patients achieving ACR20 and 23% achieving minimal disease activity.

Although methotrexate monotherapy has clearly demonstrated benefit in the treatment of rheumatoid arthritis, the evidence of this treatment has been mixed in psoriatic arthritis, with studies like the Tight Control in PsA (TICOPA) study and the RESPOND trial showing potential benefit, and the Methotrexate in Psoriatic Arthritis (MIPA) trial showing no significant advantage of methotrexate over placebo.2-4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: PsA Resource Center, Psoriatic Arthritis

You Might Also Like:
  • Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails
  • Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • Secukinumab Effective for Psoriatic Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)